177 related articles for article (PubMed ID: 23167271)
1. Structural characterization of the highly cyclized lantibiotic paenicidin A via a partial desulfurization/reduction strategy.
Lohans CT; Huang Z; van Belkum MJ; Giroud M; Sit CS; Steels EM; Zheng J; Whittal RM; McMullen LM; Vederas JC
J Am Chem Soc; 2012 Dec; 134(48):19540-3. PubMed ID: 23167271
[TBL] [Abstract][Full Text] [Related]
2. Biochemical, structural, and genetic characterization of tridecaptin A₁, an antagonist of Campylobacter jejuni.
Lohans CT; van Belkum MJ; Cochrane SA; Huang Z; Sit CS; McMullen LM; Vederas JC
Chembiochem; 2014 Jan; 15(2):243-9. PubMed ID: 24382692
[TBL] [Abstract][Full Text] [Related]
3. Structure of subtilosin A, a cyclic antimicrobial peptide from Bacillus subtilis with unusual sulfur to alpha-carbon cross-links: formation and reduction of alpha-thio-alpha-amino acid derivatives.
Kawulka KE; Sprules T; Diaper CM; Whittal RM; McKay RT; Mercier P; Zuber P; Vederas JC
Biochemistry; 2004 Mar; 43(12):3385-95. PubMed ID: 15035610
[TBL] [Abstract][Full Text] [Related]
4. Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity.
Martin NI; Sprules T; Carpenter MR; Cotter PD; Hill C; Ross RP; Vederas JC
Biochemistry; 2004 Mar; 43(11):3049-56. PubMed ID: 15023056
[TBL] [Abstract][Full Text] [Related]
5. Structural characterization of thioether-bridged bacteriocins.
Lohans CT; Vederas JC
J Antibiot (Tokyo); 2014 Jan; 67(1):23-30. PubMed ID: 24022605
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the Antimicrobial Peptide Penisin, a Class Ia Novel Lantibiotic from Paenibacillus sp. Strain A3.
Baindara P; Chaudhry V; Mittal G; Liao LM; Matos CO; Khatri N; Franco OL; Patil PB; Korpole S
Antimicrob Agents Chemother; 2016 Jan; 60(1):580-91. PubMed ID: 26574006
[TBL] [Abstract][Full Text] [Related]
7. Curvopeptin: a new lanthionine-containing class III lantibiotic and its co-substrate promiscuous synthetase.
Krawczyk B; Völler GH; Völler J; Ensle P; Süssmuth RD
Chembiochem; 2012 Sep; 13(14):2065-71. PubMed ID: 22907786
[TBL] [Abstract][Full Text] [Related]
8. Characterization of new class III lantibiotics--erythreapeptin, avermipeptin and griseopeptin from Saccharopolyspora erythraea, Streptomyces avermitilis and Streptomyces griseus demonstrates stepwise N-terminal leader processing.
Völler GH; Krawczyk JM; Pesic A; Krawczyk B; Nachtigall J; Süssmuth RD
Chembiochem; 2012 May; 13(8):1174-83. PubMed ID: 22556031
[TBL] [Abstract][Full Text] [Related]
9. Structure and biosynthesis of carnolysin, a homologue of enterococcal cytolysin with D-amino acids.
Lohans CT; Li JL; Vederas JC
J Am Chem Soc; 2014 Sep; 136(38):13150-3. PubMed ID: 25207953
[TBL] [Abstract][Full Text] [Related]
10. Solid supported chemical syntheses of both components of the lantibiotic lacticin 3147.
Liu W; Chan AS; Liu H; Cochrane SA; Vederas JC
J Am Chem Soc; 2011 Sep; 133(36):14216-9. PubMed ID: 21848315
[TBL] [Abstract][Full Text] [Related]
11. Posttranslationally modified bacteriocins--the lantibiotics.
Guder A; Wiedemann I; Sahl HG
Biopolymers; 2000; 55(1):62-73. PubMed ID: 10931442
[TBL] [Abstract][Full Text] [Related]
12. The structure of the lantibiotic lacticin 481 produced by Lactococcus lactis: location of the thioether bridges.
van den Hooven HW; Lagerwerf FM; Heerma W; Haverkamp J; Piard JC; Hilbers CW; Siezen RJ; Kuipers OP; Rollema HS
FEBS Lett; 1996 Aug; 391(3):317-22. PubMed ID: 8764998
[TBL] [Abstract][Full Text] [Related]
13. Pseudomycoicidin, a Class II Lantibiotic from Bacillus pseudomycoides.
Basi-Chipalu S; Dischinger J; Josten M; Szekat C; Zweynert A; Sahl HG; Bierbaum G
Appl Environ Microbiol; 2015 May; 81(10):3419-29. PubMed ID: 25769830
[TBL] [Abstract][Full Text] [Related]
14. Isolation and structural characterization of epilancin 15X, a novel lantibiotic from a clinical strain of Staphylococcus epidermidis.
Ekkelenkamp MB; Hanssen M; Danny Hsu ST; de Jong A; Milatovic D; Verhoef J; van Nuland NA
FEBS Lett; 2005 Mar; 579(9):1917-22. PubMed ID: 15792796
[TBL] [Abstract][Full Text] [Related]
15. Studies on tridecaptin B(1), a lipopeptide with activity against multidrug resistant Gram-negative bacteria.
Cochrane SA; Lohans CT; van Belkum MJ; Bels MA; Vederas JC
Org Biomol Chem; 2015 Jun; 13(21):6073-81. PubMed ID: 25959079
[TBL] [Abstract][Full Text] [Related]
16. Lantibiotics: promising candidates for future applications in health care.
Dischinger J; Basi Chipalu S; Bierbaum G
Int J Med Microbiol; 2014 Jan; 304(1):51-62. PubMed ID: 24210177
[TBL] [Abstract][Full Text] [Related]
17. Structure and dynamics of the lantibiotic mutacin 1140.
Smith L; Zachariah C; Thirumoorthy R; Rocca J; Novák J; Hillman JD; Edison AS
Biochemistry; 2003 Sep; 42(35):10372-84. PubMed ID: 12950164
[TBL] [Abstract][Full Text] [Related]
18. Strategies for the isolation and characterization of antibacterial lantibiotics.
Jabes D; Donadio S
Methods Mol Biol; 2010; 618():31-45. PubMed ID: 20094856
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the congeners in the lantibiotic NAI-107 complex.
Maffioli SI; Iorio M; Sosio M; Monciardini P; Gaspari E; Donadio S
J Nat Prod; 2014 Jan; 77(1):79-84. PubMed ID: 24422756
[TBL] [Abstract][Full Text] [Related]
20. Sequence analysis of lantibiotics: chemical derivatization procedures allow a fast access to complete Edman degradation.
Meyer HE; Heber M; Eisermann B; Korte H; Metzger JW; Jung G
Anal Biochem; 1994 Dec; 223(2):185-90. PubMed ID: 7887461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
